Summary of patient characteristics across WHO 2017 blast-based subgroups
| Variable . | Entire group . | CMML-0 . | CMML-1 . | CMML-2 . | P* . | ||
|---|---|---|---|---|---|---|---|
| Overall . | CMML-0 vs 1 . | CMML-0/1 vs 2 . | |||||
| Patients, N (%) | 629 | 214 (34.0) | 214 (34.0) | 201 (32.0) | |||
| Age, median (range), y | 69.9 (24.8-91.1) | 69.9 (31.2-91.1) | 69.3 (24.8-87.6) | 70.3 (27.5-86.7) | .0686 | .0764 | .1446 |
| Age group, n (%), y | |||||||
| <60 | 116 (18.4) | 35 (16.4) | 53 (24.8) | 28 (13.9) | .0534 | .0850 | .1348 |
| 60-69 | 203 (32.3) | 73 (34.1) | 61 (28.5) | 69 (34.3) | |||
| ≥70 | 310 (49.3) | 106 (49.5) | 100 (46.7) | 104 (51.7) | |||
| Sex, n (%) | |||||||
| Female | 199 (31.6) | 70 (32.7) | 57 (26.6) | 72 (35.8) | .1215 | .1690 | .1221 |
| Male | 430 (68.4) | 144 (67.3) | 157 (73.4) | 129 (64.2) | |||
| FAB subtype, n (%) | |||||||
| MDS-CMML | 306 (48.6) | 122 (57.0) | 101 (47.2) | 83 (41.3) | .0052 | .0422 | .0114 |
| MP-CMML | 323 (51.4) | 92 (43.0) | 113 (52.8) | 118 (58.7) | |||
| PB parameters | |||||||
| WBC count, median (range), ×109/L | 13.2 (0.8-223.1) | 11.3 (0.8-149.8) | 13.3 (1.3-211.8) | 17.2 (1.1-223.1) | .0009 | .0287 | .0027 |
| Hemoglobin concentration, median (range), g/dL | 10.4 (5.1-16.4) | 10.7 (5.1-16.4) | 10.6 (5.9-15.7) | 9.9 (5.3-16.0) | .0119 | .4335 | .0041 |
| Platelet count, median (range), ×109/L | 92.0 (2.0-1554.0) | 110.0 (7.0-1554) | 88.0 (6.0-912.0) | 81.0 (2.0-606.0) | .0001 | .0091 | .0009 |
| Immature myeloid cells,† median (minimum-maximum) | 3.0 (0.0-50.0) | 1.0 (0.0-34.0) | 4.0 (0.0-50.0) | 6.0 (0.0-50.0) | <.0001 | <.0001 | <.0001 |
| LDH, median (range), IU/L | 610.0 (142.0-11 060.0) | 551.0 (142-11 060) | 662.5 (191-6372) | 662.5 (250-9997) | <.0001 | .0001 | .0005 |
| BM blast percentage, median (range) | 6.0 (0.0-19.0) | 2.0 (0.0-4.0) | 6.0 (0.0-9.0) | 12.0 (1.0-19.0) | <.0001 | <.0001 | <.0001 |
| MDAPS group, n (%) | |||||||
| High | 104 (16.5) | 0 (0) | 0 (0) | 104 (51.7) | <.0001 | .0057 | <.0001 |
| Intermediate-2 | 284 (45.2) | 88 (41.1) | 118 (55.1) | 78 (38.8) | |||
| Intermediate-1 | 176 (28.0) | 85 (39.7) | 73 (34.1) | 18 (9.0) | |||
| Low | 65 (10.3) | 41 (19.2) | 23 (10.7) | 1 (0.5) | |||
| CPSS group, n (%) | |||||||
| HIGH | 65 (10.3) | 5 (2.3) | 10 (4.7) | 50 (24.9) | <.0001 | .3673 | <.0001 |
| INT-2 | 263 (41.8) | 73 (34.1) | 71 (33.2) | 119 (59.2) | |||
| INT-1 | 186 (29.6) | 73 (34.1) | 81 (37.9) | 32 (15.9) | |||
| Low | 115 (18.3) | 63 (29.4) | 52 (24.3) | 0 (0) | |||
| CPSS cytogenetic risk groups, n (%) | |||||||
| High | 108 (17.2) | 24 (11.2) | 28 (13.1) | 56 (27.9) | .0001 | .8356 | <.0001 |
| Intermediate | 94 (14.9) | 33 (15.4) | 33 (15.4) | 28 (13.9) | |||
| Low | 427 (67.9) | 157 (73.4) | 153 (71.5) | 117 (58.2) | |||
| Tang cytogenetic risk groups, n (%) | |||||||
| High | 72 (11.4) | 14 (6.5) | 22 (10.3) | 36 (17.9) | .0013 | .3634 | .0003 |
| Intermediate | 130 (20.7) | 43 (20.1) | 39 (18.2) | 48 (23.9) | |||
| Low | 427 (67.9) | 157 (73.4) | 153 (71.5) | 117 (58.2) | |||
| Mutations, present, n (%) | |||||||
| TET2 | 75 (40.3) | 35 (47.9) | 18 (30.5) | 22 (40.7) | .1269 | .0422‡ | .9407 |
| ASXL1 | 62 (44.3) | 23 (40.4) | 18 (43.9) | 21 (50.0) | .6326 | .7251 | .3729 |
| RAS | 130 (27.0) | 37 (23.0) | 49 (29.3) | 44 (28.6) | .3720 | .1905§ | .5875 |
| TP53 | 10 (5.4) | 6 (8.2) | 2 (3.4) | 2 (3.7) | .3840 | .2476 | .5177 |
| RUNX1 | 28 (20.0) | 11 (19.3) | 10 (24.4) | 7 (16.7) | .6693 | .5445 | .5186 |
| Follow-up duration, median (range), mo | 19.6 (0.0-191.9) | 23.7 (0.0-185.2) | 21.6 (0.0-171.0) | 16.1 (0.0-191.9) | .0001 | .1532 | <.0001 |
| Death, n (%) | 432 (68.7) | 131 (61.2) | 152 (71.0) | 149 (74.1) | .0119 | .0320 | .0435 |
| Survival time, median (95% CI), mo | 26.3 (24.3-29.2) | 35.0 (26.7-42.8) | 28.1 (24.5-32.3) | 19.4 (17.4-23.4) | <.0001 | .0110 | <.0001 |
| Duration to AML transformation, median (range), mo | 17.7 (0.0-185.2) | 22.6 (0.0-185.2) | 17.4 (0.0-171.0) | 13.4 (0.0-172.1) | <.0001 | .1045 | <.0001 |
| AML, n (%) | 110 (17.5) | 27 (12.6) | 42 (19.6) | 41 (20.4) | .0680 | .0486 | .1880 |
| Variable . | Entire group . | CMML-0 . | CMML-1 . | CMML-2 . | P* . | ||
|---|---|---|---|---|---|---|---|
| Overall . | CMML-0 vs 1 . | CMML-0/1 vs 2 . | |||||
| Patients, N (%) | 629 | 214 (34.0) | 214 (34.0) | 201 (32.0) | |||
| Age, median (range), y | 69.9 (24.8-91.1) | 69.9 (31.2-91.1) | 69.3 (24.8-87.6) | 70.3 (27.5-86.7) | .0686 | .0764 | .1446 |
| Age group, n (%), y | |||||||
| <60 | 116 (18.4) | 35 (16.4) | 53 (24.8) | 28 (13.9) | .0534 | .0850 | .1348 |
| 60-69 | 203 (32.3) | 73 (34.1) | 61 (28.5) | 69 (34.3) | |||
| ≥70 | 310 (49.3) | 106 (49.5) | 100 (46.7) | 104 (51.7) | |||
| Sex, n (%) | |||||||
| Female | 199 (31.6) | 70 (32.7) | 57 (26.6) | 72 (35.8) | .1215 | .1690 | .1221 |
| Male | 430 (68.4) | 144 (67.3) | 157 (73.4) | 129 (64.2) | |||
| FAB subtype, n (%) | |||||||
| MDS-CMML | 306 (48.6) | 122 (57.0) | 101 (47.2) | 83 (41.3) | .0052 | .0422 | .0114 |
| MP-CMML | 323 (51.4) | 92 (43.0) | 113 (52.8) | 118 (58.7) | |||
| PB parameters | |||||||
| WBC count, median (range), ×109/L | 13.2 (0.8-223.1) | 11.3 (0.8-149.8) | 13.3 (1.3-211.8) | 17.2 (1.1-223.1) | .0009 | .0287 | .0027 |
| Hemoglobin concentration, median (range), g/dL | 10.4 (5.1-16.4) | 10.7 (5.1-16.4) | 10.6 (5.9-15.7) | 9.9 (5.3-16.0) | .0119 | .4335 | .0041 |
| Platelet count, median (range), ×109/L | 92.0 (2.0-1554.0) | 110.0 (7.0-1554) | 88.0 (6.0-912.0) | 81.0 (2.0-606.0) | .0001 | .0091 | .0009 |
| Immature myeloid cells,† median (minimum-maximum) | 3.0 (0.0-50.0) | 1.0 (0.0-34.0) | 4.0 (0.0-50.0) | 6.0 (0.0-50.0) | <.0001 | <.0001 | <.0001 |
| LDH, median (range), IU/L | 610.0 (142.0-11 060.0) | 551.0 (142-11 060) | 662.5 (191-6372) | 662.5 (250-9997) | <.0001 | .0001 | .0005 |
| BM blast percentage, median (range) | 6.0 (0.0-19.0) | 2.0 (0.0-4.0) | 6.0 (0.0-9.0) | 12.0 (1.0-19.0) | <.0001 | <.0001 | <.0001 |
| MDAPS group, n (%) | |||||||
| High | 104 (16.5) | 0 (0) | 0 (0) | 104 (51.7) | <.0001 | .0057 | <.0001 |
| Intermediate-2 | 284 (45.2) | 88 (41.1) | 118 (55.1) | 78 (38.8) | |||
| Intermediate-1 | 176 (28.0) | 85 (39.7) | 73 (34.1) | 18 (9.0) | |||
| Low | 65 (10.3) | 41 (19.2) | 23 (10.7) | 1 (0.5) | |||
| CPSS group, n (%) | |||||||
| HIGH | 65 (10.3) | 5 (2.3) | 10 (4.7) | 50 (24.9) | <.0001 | .3673 | <.0001 |
| INT-2 | 263 (41.8) | 73 (34.1) | 71 (33.2) | 119 (59.2) | |||
| INT-1 | 186 (29.6) | 73 (34.1) | 81 (37.9) | 32 (15.9) | |||
| Low | 115 (18.3) | 63 (29.4) | 52 (24.3) | 0 (0) | |||
| CPSS cytogenetic risk groups, n (%) | |||||||
| High | 108 (17.2) | 24 (11.2) | 28 (13.1) | 56 (27.9) | .0001 | .8356 | <.0001 |
| Intermediate | 94 (14.9) | 33 (15.4) | 33 (15.4) | 28 (13.9) | |||
| Low | 427 (67.9) | 157 (73.4) | 153 (71.5) | 117 (58.2) | |||
| Tang cytogenetic risk groups, n (%) | |||||||
| High | 72 (11.4) | 14 (6.5) | 22 (10.3) | 36 (17.9) | .0013 | .3634 | .0003 |
| Intermediate | 130 (20.7) | 43 (20.1) | 39 (18.2) | 48 (23.9) | |||
| Low | 427 (67.9) | 157 (73.4) | 153 (71.5) | 117 (58.2) | |||
| Mutations, present, n (%) | |||||||
| TET2 | 75 (40.3) | 35 (47.9) | 18 (30.5) | 22 (40.7) | .1269 | .0422‡ | .9407 |
| ASXL1 | 62 (44.3) | 23 (40.4) | 18 (43.9) | 21 (50.0) | .6326 | .7251 | .3729 |
| RAS | 130 (27.0) | 37 (23.0) | 49 (29.3) | 44 (28.6) | .3720 | .1905§ | .5875 |
| TP53 | 10 (5.4) | 6 (8.2) | 2 (3.4) | 2 (3.7) | .3840 | .2476 | .5177 |
| RUNX1 | 28 (20.0) | 11 (19.3) | 10 (24.4) | 7 (16.7) | .6693 | .5445 | .5186 |
| Follow-up duration, median (range), mo | 19.6 (0.0-191.9) | 23.7 (0.0-185.2) | 21.6 (0.0-171.0) | 16.1 (0.0-191.9) | .0001 | .1532 | <.0001 |
| Death, n (%) | 432 (68.7) | 131 (61.2) | 152 (71.0) | 149 (74.1) | .0119 | .0320 | .0435 |
| Survival time, median (95% CI), mo | 26.3 (24.3-29.2) | 35.0 (26.7-42.8) | 28.1 (24.5-32.3) | 19.4 (17.4-23.4) | <.0001 | .0110 | <.0001 |
| Duration to AML transformation, median (range), mo | 17.7 (0.0-185.2) | 22.6 (0.0-185.2) | 17.4 (0.0-171.0) | 13.4 (0.0-172.1) | <.0001 | .1045 | <.0001 |
| AML, n (%) | 110 (17.5) | 27 (12.6) | 42 (19.6) | 41 (20.4) | .0680 | .0486 | .1880 |
Full comparison conducted using treatment-naïve group (n = 499) showed comparable results with exceptions noted (see ‡ and §).
Kruskal-Wallis test and Wilcoxon rank-sum test for continuous factors and χ2 test for categorical factors as appropriate.
Sum of promyelocytes, myelocytes, and metamyelocytes in PB.
P not significant (.2026) in treatment-naïve group.
P is significant (.0376) in treatment-naïve group.